And early data suggests it may help preserve lean muscle mass during rapid weight loss, a problem that plagues every GLP-1 based medication on the market
The profound impact on weight management and metabolic health has positioned these drugs as game-changers in the treatment landscape for obesity and type 2 diabetes
Expert Opinion on Investigational Drugs
Planning ahead prevents gaps in your protocol, and the peptide cost calculator can help you estimate total research costs across the full escalation schedule
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial